Literature DB >> 9343238

Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.

J E Conway1, S Zolotukhin, N Muzyczka, G S Hayward, B J Byrne.   

Abstract

Recombinant adeno-associated virus (AAV) type 2 (rAAV) vectors have recently been shown to have great utility as gene transfer agents both in vitro and in vivo. One of the problems associated with the use of rAAV vectors has been the difficulty of large-scale vector production. Low-efficiency plasmid transfection of the rAAV vector and complementing AAV type 2 (AAV-2) functions (rep and cap) followed by superinfection with adenovirus has been the standard approach to rAAV production. The objectives of this study were to demonstrate the ability of a recombinant herpes simplex virus type 1 (HSV-1) amplicon expressing AAV-2 Rep and Cap to support replication and packaging of rAAV vectors. HSV-1 amplicon vectors were constructed which contain the AAV-2 rep and cap genes under control of their native promoters (p5, p19, and p40). An HSV-1 amplicon vector, HSV-RC/KOS or HSV-RC/d27, was generated by supplying helper functions with either wild-type HSV-1 (KOS strain) or the ICP27-deleted mutant of HSV-1, d27-1, respectively. Replication of the amplicon stocks is not inhibited by the presence of AAV-2 Rep proteins, which highlights important differences between HSV-1 and adenovirus replication and the mechanism of providing helper function for productive AAV infection. Coinfection of rAAV and HSV-RC/KOS resulted in the replication and amplification of rAAV genomes. Similarly, rescue and replication of rAAV genomes occurred when rAAV vector plasmids were transfected into cells followed by HSV-RC/KOS infection and when two rAAV proviral cell lines were infected with HSV-RC/KOS or HSV-RC/d27. Production of infectious rAAV by rescue from two rAAV proviral cell lines has also been achieved with HSV-RC/KOS and HSV-RC/d27. The particle titer of rAAV produced with HSV-RC/d27 is equal to that achieved by supplying rep and cap by transfection followed by adenovirus superinfection. Importantly, no detectable wild-type AAV-2 is generated with this approach. These results demonstrate that an HSV-1 amplicon expressing the AAV-2 genes rep and cap along with HSV-1 helper functions supports the replication and packaging of rAAV vectors in a scaleable process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343238      PMCID: PMC192344     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products.

Authors:  K A Vincent; S T Piraino; S C Wadsworth
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  In vivo model of adeno-associated virus vector persistence and rescue.

Authors:  S A Afione; C K Conrad; W G Kearns; S Chunduru; R Adams; T C Reynolds; W B Guggino; G R Cutting; B J Carter; T R Flotte
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers.

Authors:  M D Weitzman; K J Fisher; J M Wilson
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.

Authors:  S Zolotukhin; M Potter; W W Hauswirth; J Guy; N Muzyczka
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.

Authors:  K R Clark; F Voulgaropoulou; P R Johnson
Journal:  Gene Ther       Date:  1996-12       Impact factor: 5.250

7.  The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection.

Authors:  D J Pereira; D M McCarty; N Muzyczka
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography.

Authors:  K Tamayose; Y Hirai; T Shimada
Journal:  Hum Gene Ther       Date:  1996-03-01       Impact factor: 5.695

9.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.

Authors:  P D Kessler; G M Podsakoff; X Chen; S A McQuiston; P C Colosi; L A Matelis; G J Kurtzman; B J Byrne
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

10.  Cell lines for the production of recombinant adeno-associated virus.

Authors:  K R Clark; F Voulgaropoulou; D M Fraley; P R Johnson
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

View more
  34 in total

1.  Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.

Authors:  A Lieber; D S Steinwaerder; C A Carlson; M A Kay
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.

Authors:  A Recchia; R J Parks; S Lamartina; C Toniatti; L Pieroni; F Palombo; G Ciliberto; F L Graham; R Cortese; N La Monica; S Colloca
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Rep-dependent initiation of adeno-associated virus type 2 DNA replication by a herpes simplex virus type 1 replication complex in a reconstituted system.

Authors:  P Ward; M Falkenberg; P Elias; M Weitzman; R M Linden
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 4.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

5.  Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size.

Authors:  G E Tullis; T Shenk
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 6.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

Review 7.  Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

Authors:  Ronald J Mandel; Corinna Burger; Richard O Snyder
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

Review 8.  Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies.

Authors:  Nathalie Clément; David R Knop; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

Review 9.  Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.

Authors:  Tamas Virag; Sylvain Cecchini; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

10.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors.

Authors:  Anna Paula de Oliveira; Cornel Fraefel
Journal:  Open Virol J       Date:  2010-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.